| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - The cliThe clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a separation of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was sufficient. With the invention of new treatment types a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) role was detected in adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs) started, sub-classification of NSCLC and molecular analysis of the tumor was asked for. Pathologists submit not just a diagnosis, but are involved in a multidisciplinary team for lung cancer management. After EGFR, several other driver genes such as EML4-ALK1, ROS1, DDR2, FGFR1 were discovered, and more will come. Due to new developments in bronchology the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many of driver gene aberrations are inversions or translocations and thus require FISH analysis, each requires a certain amount of tumor cells from an already limited amount. In this respect new genetic test systems have been introduced such as next generation sequencing, which enables to detect multiple mutations at once, as well as amplifications and fusion genes. As soon as these methods are validated for routine use this will enable the analysis of multiple genetic changes simultaneously. In this review we focus on genetic changes in NSCLC, resistance to new target therapies, and also to requirements for a meaningful evaluation of lung cancer tissue and cells.
- The cliThe clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a separation of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was sufficient. With the invention of new treatment types a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) role was detected in adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs) started, sub-classification of NSCLC and molecular analysis of the tumor was asked for. Pathologists submit not just a diagnosis, but are involved in a multidisciplinary team for lung cancer management. After EGFR, several other driver genes such as EML4-ALK1, ROS1, DDR2, FGFR1 were discovered, and more will come. Due to new developments in bronchology the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many of driver gene aberrations are inversions or translocations and thus require FISH analysis, each requires a certain amount of tumor cells from an already limited amount. In this respect new genetic test systems have been introduced such as next generation sequencing, which enables to detect multiple mutations at once, as well as amplifications and fusion genes. As soon as these methods are validated for routine use this will enable the analysis of multiple genetic changes simultaneously. In this review we focus on genetic changes in NSCLC, resistance to new target therapies, and also to requirements for a meaningful evaluation of lung cancer tissue and cells. (en)
|
| Title
| - Molecular testing in lung cancer in the era of precision medicine
- Molecular testing in lung cancer in the era of precision medicine (en)
|
| skos:prefLabel
| - Molecular testing in lung cancer in the era of precision medicine
- Molecular testing in lung cancer in the era of precision medicine (en)
|
| skos:notation
| - RIV/00216208:11150/14:10283673!RIV15-MSM-11150___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11150/14:10283673
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - requirements; molecular testing; lung cancer (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - TLCR Translational lung cancer research
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Ryška, Aleš
- Olszewski, Wlodzimierz
- Popper, Helmut H.
- Tímár, Jozsef
|
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| - 10.3978/j.issn.2218-6751.2014.10.01
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)